CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
The CTS 2020 Annual Laboratory Survey is on its way to your email box. We would appreciate you takin...
IPFA welcomes Marion Lanteri as Executive Board member, CTS as new member organization
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
Through communications with our clients, CTS is aware of the current national blood shortage. We rea...
The recent communication regarding the recent Anti-SARS-CoV-2 Total assay in Tampa has brought about...